Assessment of ex vivo pharmacodynamic markers during inhibition of thrombosis by CI-1031 (ZK-807834), a novel direct factor Xa inhibitor

Pharmacology

Volumn 64, Issue 2, 2002, Pages 76-83

  Chi, Liguo ^a   Pen, Yun Wen ^a   Potoczak, Ronald ^a   Gibson, Glenn ^a   Hicks, Gary ^a   Mertz, Thomas E ^a   Janiczek, Nancy ^a   Juneau, Paul L ^a   Gallagher, Kim ^a   Leadley, Robert ^a  

^a PFIZER INC   (United States)

Author keywords

Anticoagulants; Antithrombotics; CI 1031 (ZK 807834); Factor Xa; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; N [2 (5 AMIDINO 2 HYDROXYPHENOXY) 3,5 DIFLUORO 6 [3 (1 METHYL 1H 2 IMIDAZOLIN 2 YL)PHENOXY] 4 PYRIDINYL] N METHYLGLYCINE; N [2 [5 [AMINO(IMINO)METHYL 2 HYDROXYPHENOXY] 3,5 DIFLUORO 6 [3 (4,5 DIHYDRO 1 METHYL 1H IMIDAZOL 2 YL)PHENOXY]PYRIDIN 4 YL] N METHYLGLYCINE]; UNCLASSIFIED DRUG;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLEEDING; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; DRUG MECHANISM; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTHROMBIN TIME; RABBIT; RELIABILITY; THROMBOGENESIS; THROMBOSIS; TIME;

AMIDINES; ANIMALS; ANTICOAGULANTS; BIOLOGICAL MARKERS; BLOOD COAGULATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; HUMANS; PARTIAL THROMBOPLASTIN TIME; PLATELET AGGREGATION; PROTHROMBIN TIME; PYRIDINES; RABBITS; VENOUS THROMBOSIS;

EID: 18244397236     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000056154     Document Type: Article

References (45)

1. Oral anticoagulant drugs
2. Antithrombotic agents and thromboembolic disease
3. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by anti-thrombin III-independent inhibitors
4. Preclinical studies on a low molecular weight heparin
5. Low-molecular-weight heparins
6. Heparin-associated thrombocytopenia treatment with low molecular weight heparin
7. Recombinant hirudin (Lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia
8. Recombinant hirudin: A perspective
9. Hirulog: A direct thrombin inhibitor for management of acute coronary syndromes
10. Direct thrombin inhibition and thrombolytic therapy: Rationale for the hirulog and early reperfusion/occlusion (HERO-2) trial
11. Organisation to assess strategies for ischemic syndromes (OASIS-2) investigators: Effects of recombinant hirudin (lepirudin) compared with heparin on death myocardial infarction, refractory angina, revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: A randomised trial
12. Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial
13. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
14. Synthetic inhibitors of thrombin and factor Xa: From bench to bedside
15. Coagulation factor Xa: The prothrombinase complex as an emerging therapeutic target for small molecule inhibitors
16. Coagulation cascade: An overview
17. Primary prevention of coronary arterial thrombosis with the factor Xa inhibitor rTAP in a canine electrolytic injury model
18. Antithrombotic efficacy of a recombinant nematode anticoagulant peptide (rNAP5) in canine models of thrombosis after single subcutaneous administration
19. Synthetic inhibitors of coagulation factor Xa
20. Anti-thrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis
21. Pharmacodynamic activity and antithrombotic efficacy of RPR120844, a novel inhibitor of coagulation factor Xa
22. YM-60828, a novel factor Xa inhibitor: Separation of its anti-thrombotic effects from its prolongation of bleeding time
23. Comparison of the anticoagulant and antithrombotic effects of YM-75466, a novel orally-active factor Xa inhibitor, and warfarin in mice
24. Discovery of N-(2-(5-(amino(imi-no)methyl)-2-hydroxyphenoxy)-3,5-difluoro-6-(3-(4,5- dihydro-1-methyl-1h-imidazol-2yl)-phenoxy)pyridin-4-yl)-n-methylglycine (ZK-807834): A potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa
25. A novel inhibitor of factor Xa accelerates coronary fibrinolysis and improves long-term patency in dogs
26. The efficacy and safety of BX-807834, a potent, selective factor Xa inhibitor in animal models
27. Effects of ZK-807834, a novel inhibitor of factor Xa, on arterial and venous thrombosis in rabbits
28. A novel model of venous thrombosis in the vena cava of rabbits
29. A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein thrombosis
30. In vitro inhibition of factor Xa and prothrombinase by BX-807834, a potent selective active site inhibitor
31. Importance of factor Xa in determining the procoagulant activity of whole-blood clots
32. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots
33. Low molecular weight heparin decreases proximal and distal deep venous thrombosis following total knee arthroplasty
34. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
35. A clinical review of the selective factor Xa inhibitors
36. Tolerability, pharmacokinetics, and pharmaco-dynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers
37. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa
38. Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis
39. RPR120844, a novel, specific inhibitor of coagulation factor Xa inhibits venous thrombosis in the rabbit
40. Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa
41. Multicenter evaluation of a new chromogenic factor X assay in plasma of patients on oral anticoagulants
42. Monitoring warfarin therapy in patients with lupus anticoagulants
43. An international standard for low molecular weight heparin
44. Pharmacokinetics and tolerability of a new low molecular mass heparin (RO-11) in healthy volunteers. A dose-finding study within the therapeutical range
45. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor